Thomas Egger, teg@te-communications.ch 
www.bbbiotech.com 
Company profile 
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in 
Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are 
mainly located in the US and Western Europe. 
BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its 
distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of 
Bellevue Asset Management AG when making its investment decisions. 
Disclaimer 
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such 
statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject 
to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and 
its directors and officers accept no responsibility in that regard. All forward-looking statements included in this 
release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation 
to update any forward-looking statements as a result of new information, future events or other factors. 
Composition of BB Biotech's portfolio as of December 31, 2020 
(in % of securities, rounded values) 
Ionis Pharmaceuticals                      10.4% 
Moderna                                     6.7% 
Neurocrine Biosciences                      6.5% 
Argenx SE                                   6.1% 
Incyte                                      5.6% 
 
Vertex Pharmaceuticals                      4.8% 
Alexion Pharmaceuticals                     4.5% 
Arvinas                                     4.1% 
Fate Therapeutics                           4.1% 
Agios Pharmaceuticals                       4.0% 
Halozyme Therapeutics                       3.8% 
Alnylam Pharmaceuticals                     3.4% 
Crispr Therapeutics                         3.1% 
Sage Therapeutics                           3.0% 
Radius Health                               3.0% 
Biogen                                      2.9% 
Myovant Sciences                            2.9% 
Intra-Cellular Therapies                    2.5% 
Macrogenics                                 2.5% 
Scholar Rock Holding                        2.5% 
Esperion Therapeutics                       2.3% 
Generation Bio Co.                          1.5% 
Molecular Templates                         1.3% 
Relay Therapeutics                          1.3% 
Exelixis                                    1.3% 
Mersana Therapeutics                        1.1% 
Nektar Therapeutics                         1.0% 
Black Diamond Therapeutics                  1.0% 
Beam Therapeutics                           0.7% 
Kezar Life Sciences                         0.5% 
Wave Life Sciences                          0.5% 
Homology Medicines                          0.4% 
Voyager Therapeutics                        0.4% 
Cidara Therapeutics                         0.1% 
 
Alder Biopharmaceuticals - CVR              0.1% 
 
Total securities                  CHF 3 954.7 mn 
 
Other assets                          CHF 8.4 mn 
Other payables                     CHF (75.6) mn 
 
Net Asset Value                   CHF 3 887.5 mn 
 ----------------------------------------------------------------------------------------------------------------------- 

2021-01-22 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1162360 
 
End of News   DGAP News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 22, 2021 01:06 ET (06:06 GMT)